• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Recombinant Human Coagulation Factors

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

IDELVION® for Hemophilia B Now Available in US

21 March 2016 - Long-acting recombinant Factor IX

Learn more

Novel Recombinant Hemophilia Treatments

CSL Behring’s recombinant factor development pipeline is built on its strength in protein research and development and scientific expertise in bleeding disorders

Learn more

Indications

Recombinant factor VIII and IX, used widely in the treatment of hemophilia A and B respectively, were the first commercially available functional proteins to treat bleeding disorders. Both are widely used in the treatment of hemophilia A and B respectively.14

Recombinant human coagulation factor VIIa (rFVIIa) is structurally similar to human plasma-derived factor VIIa. When complexed with tissue factor, it can activate coagulation Factor IX and X. rFVIIa is indicated for:15

  • Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, and in patients with acquired hemophilia
  • Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, and in patients with acquired hemophilia
  • Treatment of bleeding episodes in patients with congenital FVII deficiency
  • Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency

CSL Behring recombinant human coagulation factor products include:

Registration status and indications vary from country to country. Please contact your local CSL Behring representative and review the respective prescribing information.





Last Updated: 4/13/2016 4:20 PM
  • E-mail
  • Print
  • Share